NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week the Danish healthcare stocks outperformed their Nordic counterparts. Acarix updated its business model in the U.S. and several companies presented new data including Acarix, IO Biotech, and Initiator Pharma. Finally, Curasight and Y-mAbs Therapeutics made changes to the board and management.

8 of the 21 Danish companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Gubra is now the best-performing Danish healthcare stock year-to-date with a 126% return and Biosergen was the best Nordic healthcare investment last week.

---

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.

---

DANISH COMPANY NEWS

Acarix

Acarix announces the initiation of the first US-based clinical workflow evaluation study (Link)

Acarix adopts new growth-focused business model and provides outlook update as part of our ongoing strategic review (Link)

New Health Economic Analysis Presented at ACC Highlights The Acarix CADScor System’s Cost-Effectiveness (Link)

Ascendis Pharma

No news the past week

Biosergen

Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue (Link)

Cessatech

No news the past week

CS Medica

No news the past week

Curasight

Curasight announces change in the Board of Directors (Link)

Evaxion Biotech

No news the past week

ExpreS2ion

No news the past week

Fluoguide

No news the past week

Genmab

Transactions in Connection with Share Buy-back Program (Link)

Gubra

No news the past week

Initiator Pharma

Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology (Link)

IO Biotech

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 (Link)

Pila Pharma

No news the past week

Saniona

No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer (Link)

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a negative share price performance of the past week of 0.4%. Biosergen rose 25% after they resolved a directed issue of 481,250 units. Acarix rose 3% in a very eventful week after new data were presented, a new business model introduced as well as initiation of their first US-based clinical workflow evaluation study. Curasight announced a change of chairman from Per Falholt to Kirsten Drejer. Finally, IO Biotech and Initiator Pharma also presented new data. The best stocks year-to-date continue to be Y-mAbs Therapeutics and Gubra with 111-126% increases after the first 3.5 months of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 2.4%.

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 0.4% to 60.66. The index was recovering from its all-time low in October of 57.12 but has since been on a downward trajectory. In the past 12 months, the index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 20%.

The index development for Kapital Partner Healthcare Index the past 12 months

36-58% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

Respiratorius AB (58%) is a research company focusing on the development of drug candidates for the treatment of cancer and especially aggressive lymphoma. The company was established in 1999 as a spin-off from Lund University.

Clincal Lasterthermia Systems AB (37%) vision is to develop and streamline the treatment of solid cancer tumors, where the company sells sterile patient kits. The products are used in various cancer treatments such as in the treatment of malignant melanoma, as well as lung, liver and pancreatic cancer. The stock rose following positive data.

Diagonal Bio AB (36%) is developing a platform called Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria and fungi. In addition to the main business, the company also offers service and related ancillary services.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites